Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay

Autor: Lisa Davis, Irene L. Ch’en, Shabnam Tangri, Reinhold Pollner, Creton Kalfoglou, Nancy Valencia, Karen Thudium Mueller, Nathan Riccitelli, Jennifer Brogdon

Publikováno v: Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss, Pp 535-541 (2021)

Chimeric antigen receptor (CAR)-T cell therapies reprogram T cells to engage and eliminate cancer cells. Patients’ T cells are transduced in vitro using lentiviral or retroviral vectors containing a CAR transgene. Following infusion, CAR-T cells ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d7755d75a553b2b71806eea977b276d
https://pubmed.ncbi.nlm.nih.gov/33614827

Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay.

Autor: Davis L; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, CA, USA., Riccitelli N; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, CA, USA., Valencia N; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, CA, USA., Ch'en IL; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, CA, USA., Tangri S; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, CA, USA., Brogdon JL; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA., Kalfoglou C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Mueller KT; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA., Pollner R; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, CA, USA.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2020 Dec 10; Vol. 20, pp. 535-541. Date of Electronic Publication: 2020 Dec 10 (Print Publication: 2021).